Index RUT P/E - EPS (ttm) -1.96 Insider Own 38.59% Shs Outstand 44.45M Perf Week 7.28%
Market Cap 505.29M Forward P/E - EPS next Y -2.21 Insider Trans 7.61% Shs Float 27.37M Perf Month 7.79%
Enterprise Value 194.32M PEG - EPS next Q 0.93 Inst Own 69.76% Short Float 13.76% Perf Quarter 106.93%
Income -79.11M P/S 515.60 EPS this Y 112.13% Inst Trans 6.14% Short Ratio 3.41 Perf Half Y -46.89%
Sales 0.98M P/B 1.26 EPS next Y -350.88% ROA -24.45% Short Interest 3.77M Perf YTD -50.48%
Book/sh 9.01 P/C 1.50 EPS next 5Y 25.50% ROE -27.05% 52W High 28.99 -60.88% Perf Year -
Cash/sh 7.54 P/FCF - EPS past 3/5Y -56.62% -ROIC -18.69% 52W Low 4.17 171.94% Perf 3Y -
Dividend Est. - EV/EBITDA - Sales past 3/5Y - - Gross Margin -51.69% Volatility 5.70% 5.93% Perf 5Y -
Dividend TTM - EV/Sales 198.29 EPS Y/Y TTM - Oper. Margin -9339.10% ATR (14) 0.65 Perf 10Y -
Dividend Ex-Date - Quick Ratio 32.19 Sales Y/Y TTM - Profit Margin -8097.03% RSI (14) 63.78 Recom 1.40
Dividend Gr. 3/5Y - - Current Ratio 32.19 EPS Q/Q -53.23% SMA20 6.74% Beta - Target Price 24.25
Payout - Debt/Eq 0.06 Sales Q/Q -30.91% SMA50 20.95% Rel Volume 0.23 Prev Close 10.85
Employees 75 LT Debt/Eq 0.06 Earnings May 15 AMC SMA200 -16.12% Avg Volume 1.10M Price 11.34
IPO Oct 25, 2024 Option/Short Yes / Yes EPS/Sales Surpr. -9.50% 119.00% Trades
Volume 253,923 Change 4.52%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-23-25 Initiated H.C. Wainwright
Buy
$26
Feb-18-25 Downgrade Wells Fargo
Overweight → Equal Weight
$14
Nov-19-24 Initiated Wells Fargo
Overweight
$43
Nov-19-24 Initiated TD Cowen
Buy
Nov-19-24 Initiated JP Morgan
Overweight
$38
Nov-19-24 Initiated Cantor Fitzgerald
Overweight
$50
May-29-25 08:00AM
May-23-25 07:45AM
May-21-25 09:55AM
May-15-25 04:01PM
10:00AM
08:46AM
Loading…
08:46AM
07:45AM
01:45AM
(The Wall Street Journal)
May-14-25 04:06PM
(Investor's Business Daily) +50.97%
02:22PM
01:29PM
(Pharmaceutical Technology)
10:28AM
09:35AM
09:32AM
09:32AM
07:03AM
Loading…
07:03AM
Apr-16-25 09:55AM
Mar-31-25 02:34PM
Mar-27-25 08:00AM
Mar-14-25 11:26AM
Mar-05-25 06:59PM
Feb-26-25 08:00AM
Feb-18-25 08:00AM
Feb-14-25 06:45AM
Feb-06-25 07:48AM
Jan-06-25 07:00AM
Dec-18-24 08:00AM
Nov-21-24 11:12PM
Nov-20-24 07:00AM
05:10AM
04:41PM
Loading…
Oct-30-24 04:41PM
Oct-24-24 09:47PM
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Finer Jeffrey CEO and President Apr 02 '25 Option Exercise 2.76 50,000 138,000 821,907 Apr 04 04:13 PM Finer Jeffrey CEO and President Apr 03 '25 Option Exercise 2.76 5,000 13,800 826,907 Apr 04 04:13 PM Ezekowitz Alan Director Mar 07 '25 Buy 6.93 13,319 92,270 117,420 Mar 10 04:18 PM Ezekowitz Alan Director Mar 06 '25 Buy 6.00 41,355 248,130 104,101 Mar 06 09:02 PM Ezekowitz Alan Director Mar 05 '25 Buy 5.82 37,835 220,260 62,746 Mar 06 09:02 PM Ezekowitz Alan Director Mar 04 '25 Buy 6.35 7,491 47,544 24,911 Mar 06 09:02 PM Finer Jeffrey CEO and President Feb 25 '25 Buy 5.68 10,000 56,765 764,907 Feb 27 06:53 PM Finer Jeffrey CEO and President Feb 26 '25 Buy 5.70 4,000 22,796 768,907 Feb 27 06:53 PM Finer Jeffrey CEO and President Feb 27 '25 Buy 5.80 3,000 17,400 771,907 Feb 27 06:53 PM Labrucherie Gil M Chief Financial Officer Feb 25 '25 Buy 5.59 6,282 35,116 36,282 Feb 27 06:51 PM Labrucherie Gil M Chief Financial Officer Feb 27 '25 Buy 5.85 3,718 21,750 40,000 Feb 27 06:51 PM Third Rock Ventures VI, L.P. 10% Owner Feb 24 '25 Buy 6.00 18,861 113,147 4,211,659 Feb 26 04:15 PM Third Rock Ventures VI, L.P. 10% Owner Feb 20 '25 Buy 5.92 612,674 3,627,030 3,765,130 Feb 24 04:15 PM Third Rock Ventures VI, L.P. 10% Owner Feb 21 '25 Buy 5.94 427,668 2,540,348 4,192,798 Feb 24 04:15 PM Labrucherie Gil M Chief Financial Officer Feb 20 '25 Buy 5.88 14,500 85,234 25,000 Feb 21 06:06 PM Labrucherie Gil M Chief Financial Officer Feb 19 '25 Buy 5.51 10,500 57,813 10,500 Feb 21 06:06 PM Labrucherie Gil M Chief Financial Officer Feb 21 '25 Buy 5.85 5,000 29,250 30,000 Feb 21 06:06 PM RA CAPITAL MANAGEMENT, L.P. Director Oct 28 '24 Buy 18.00 4,170,000 75,060,000 5,523,915 Oct 30 06:12 PM Third Rock Ventures V, L.P. 10% Owner Oct 28 '24 Buy 18.00 370,500 6,669,000 6,215,591 Oct 28 04:53 PM Third Rock Ventures V, L.P. 10% Owner Oct 28 '24 Buy 18.00 279,500 5,031,000 3,152,456 Oct 28 04:53 PM
